| scholarly article | Q13442814 |
| P2093 | author name string | R J Noelle | |
| C L Vanderlugt | |||
| S D Miller | |||
| L M Howard | |||
| J D Laman | |||
| M C Dal Canto | |||
| A J Miga | |||
| P2860 | cites work | Reduction of atherosclerosis in mice by inhibition of CD40 signalling | Q24316540 |
| Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation | Q24677534 | ||
| The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells | Q30468363 | ||
| Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand | Q34367466 | ||
| Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection | Q35939463 | ||
| Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal | Q36361532 | ||
| Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease | Q36364080 | ||
| Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis | Q36365105 | ||
| Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion | Q36366300 | ||
| CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy | Q37375643 | ||
| CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis | Q37696199 | ||
| Determinant spreading and the dynamics of the autoimmune T-cell repertoire. | Q40487702 | ||
| Functions of CD40 and its ligand, gp39 (CD40L). | Q41113768 | ||
| CD40-CD40 ligand: a multifunctional receptor-ligand pair. | Q41134276 | ||
| A central role of CD40 ligand in the regulation of CD4+ T-cell responses | Q41149910 | ||
| Activation of human monocytes through CD40 induces matrix metalloproteinases | Q41198789 | ||
| The many roles of CD40 in cell-mediated inflammatory responses | Q41203088 | ||
| Epitope spreading | Q41312390 | ||
| Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction | Q41871732 | ||
| Expression of functional CD40 by vascular endothelial cells | Q41981036 | ||
| CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells | Q42453856 | ||
| B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy | Q42675165 | ||
| Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction | Q45788061 | ||
| Primary demyelination in Theiler's virus infection. An ultrastructural study | Q45882873 | ||
| CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation | Q45883525 | ||
| Visualization of specific B and T lymphocyte interactions in the lymph node | Q47892330 | ||
| Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis | Q47909971 | ||
| Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. | Q48913563 | ||
| Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. | Q52054451 | ||
| Tolerogenic forms of auto-antigens and cytokines in the induction of resistance to experimental allergic encephalomyelitis. | Q54173280 | ||
| Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis | Q56909511 | ||
| Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein | Q67537170 | ||
| Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides | Q67653169 | ||
| Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice | Q70994170 | ||
| Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE | Q71457188 | ||
| Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response | Q71555675 | ||
| Relapsing experimental allergic encephalomyelitis in the SJL/J mouse | Q71567989 | ||
| Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction | Q71691382 | ||
| Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses | Q71871115 | ||
| Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40 | Q72093299 | ||
| Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1 | Q72508363 | ||
| Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction | Q73347843 | ||
| CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice | Q73900356 | ||
| The functional significance of epitope spreading and its regulation by co-stimulatory molecules | Q77488334 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| antibody | Q79460 | ||
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 281-290 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis | |
| P478 | volume | 103 |
| Q40811737 | "Classic" myelin basic proteins are expressed in lymphoid tissue macrophages |
| Q34283011 | A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. |
| Q96299532 | A GM-CSF-neuroantigen tolerogenic vaccine elicits inefficient antigen recognition events below the CD40L triggering threshold to expand CD4+ CD25+ FOXP3+ Tregs that inhibit experimental autoimmune encephalomyelitis (EAE) |
| Q73822837 | A new primate model for multiple sclerosis in the common marmoset |
| Q35185949 | Activation of microglia by borna disease virus infection: in vitro study |
| Q47323461 | Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases. |
| Q40337403 | C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. |
| Q34466815 | CD154 blockade results in transient reduction in Theiler's murine encephalomyelitis virus-induced demyelinating disease |
| Q37365433 | CD40 and autoimmunity: the dark side of a great activator. |
| Q73336410 | CD40 engagement stimulates IL-12 p70 production by human microglial cells: basis for Th1 polarization in the CNS |
| Q48415768 | CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium |
| Q27481468 | CD40-CD40 Ligand Interactions Promote Trafficking of CD8+ T Cells into the Brain and Protection against West Nile Virus Encephalitis |
| Q35788667 | CD40-CD40 ligand disruption does not prevent hyperoxia-induced injury |
| Q35747327 | CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis |
| Q49025682 | CD40-mediated activation of T cells accelerates, but is not required for, encephalitogenic potential of myelin basic protein-recognizing T cells in a model of progressive experimental autoimmune encephalomyelitis. |
| Q43562885 | CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells |
| Q42554166 | CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation |
| Q37411386 | CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? |
| Q33851104 | Characterization of the CD154-positive and CD40-positive cellular subsets required for pathogenesis in retrovirus-induced murine immunodeficiency |
| Q36112729 | Chemokines Referee Inflammation within the Central Nervous System during Infection and Disease |
| Q38286209 | Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates |
| Q36919720 | Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. |
| Q36307642 | Controlled release strategies for modulating immune responses to promote tissue regeneration |
| Q33755275 | Determination of Genes Related to Uveitis by Utilization of the Random Walk with Restart Algorithm on a Protein-Protein Interaction Network |
| Q40759046 | Differentiated Th1 autoreactive effector cells can induce experimental autoimmune encephalomyelitis in the absence of IL-12 and CD40/CD40L interactions |
| Q35581158 | Emerging disease modifying therapies for multiple sclerosis |
| Q33858153 | Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice |
| Q39298181 | Epitope diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor reactivity |
| Q34575350 | Epitope spreading in immune-mediated diseases: implications for immunotherapy |
| Q53099338 | Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis. |
| Q34070348 | Gene therapy for autoimmune disorders |
| Q33259767 | Identification of three novel peptides that inhibit CD40-CD154 interaction |
| Q34386107 | Immunological aspects of microglia: relevance to Alzheimer's disease |
| Q35994774 | Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease |
| Q35054706 | Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation. |
| Q30810267 | Inflammation in multiple sclerosis: the good, the bad, and the complex |
| Q30849102 | Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. |
| Q81009347 | Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis |
| Q39272758 | Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity |
| Q64258735 | Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis |
| Q36963201 | Modulating co-stimulation |
| Q31100421 | Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library |
| Q36885184 | Molecular targets for disrupting leukocyte trafficking during multiple sclerosis |
| Q41660408 | Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review |
| Q92154890 | Multiple Sclerosis CD49d+CD154+ As Myelin-Specific Lymphocytes Induced During Remyelination |
| Q47844741 | Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells |
| Q34006992 | Mycobacterium bovis BCG-induced granuloma formation depends on gamma interferon and CD40 ligand but does not require CD28. |
| Q36991434 | New insights into adaptive immunity in chronic neuroinflammation |
| Q34787127 | Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis |
| Q74431968 | Novel monoclonal antibodies against proteolipid protein peptide 139-151 demonstrate demyelination and myelin uptake by macrophages in MS and marmoset EAE lesions |
| Q37754616 | Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosis |
| Q37307349 | PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. |
| Q36810295 | Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases. |
| Q34276030 | Potential biologic agents for treating rheumatoid arthritis |
| Q35022580 | Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases |
| Q38716917 | Regulatory role of cytosolic phospholipase A2 alpha in the induction of CD40 in microglia |
| Q33338408 | Role of CD40-CVD40L in mouse severe malaria |
| Q34307160 | Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis |
| Q40668935 | Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system |
| Q57083588 | T cell costimulatory blockade as a novel immune intervention in autoimmune diseases |
| Q35093604 | T cell costimulatory pathways: blockade for autoimmunity |
| Q37754572 | T-cell response dynamics in animal models of multiple sclerosis: implications for immunotherapies |
| Q78555839 | TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity |
| Q34837371 | Targeting T cell costimulation in autoimmune disease |
| Q36278572 | Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells |
| Q47221242 | The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis |
| Q34003535 | The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis. |
| Q36369234 | The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. |
| Q35294476 | The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis |
| Q24814335 | The microglial "activation" continuum: from innate to adaptive responses |
| Q59030876 | The virtue of tolerance |
| Q38499559 | Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process |
| Q35088106 | Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses |
| Q74570628 | Transient anti-CD154-mediated immunotherapy of ongoing relapsing experimental autoimmune encephalomyelitis induces long-term inhibition of disease relapses |
| Q26775820 | Translational utility of experimental autoimmune encephalomyelitis: recent developments |
Search more.